Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Mitomycin 15Gemcitabine 13dodecyl maltoside 5BCG Vaccine 5erdafitinib 4apaziquone 4ALT-803 4Epirubicin 3viscum album peptide 2durvalumab 2VB4-845 2Imiquimod 2Docetaxel 25-aminolevulinic acid hexyl ester 21-phenyl-3,3-dimethyltriazene 2vocimagene amiretrorepvec 1valrubicin 1pirarubicin 1pembrolizumab 1linrodostat 1hydroxycamptothecinum 1enfortumab vedotin 1catumaxomab 1Water 1Therapeutics 1Therapeutic Uses 1Standard of Care 1Polysorbates 1Photochemotherapy 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Non-Muscle Invasive Bladder Neoplasms × Administration, Intravesical × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔